Science
Intellectual Property
Lionheart Health holds commercialization and license rights to its core Leonhardt Ventures portfolio, supplemented by third-party licensed and optioned technologies.
- Patent and application entries
- 63
- Issued claims (owned, licensed and optioned)
- 518
- Aggregate issued, proposed and estimated claims
- 1,133
As of October 9, 2026
Portfolio summary
| Portfolio / status | Patents / applications | Claims |
|---|---|---|
| IssuedCore Leonhardt portfolio | 18 patents | 301 issued |
| PendingPublished applications | 8 applications | 135 proposed |
| In processAnnounced filings and prepared applications | 24 entries | 480 estimated |
| LicensedSchuler cancer technologies | 8 issued patents | 137 issued |
| LicensedStangl Klotho-expressing stem cells | 2 issued grants; 1 patent family | 40 issued |
| OptionedSchuler muscle and neurocode technologies | 3 issued patents | 40 issued |
| Combined working inventory | 63 entries | 1,133 aggregate |
Issued-claim subtotal: 518, including 478 within disclosed commercial/licensed portfolios and 40 associated with options.
What the portfolio covers
Bioelectric control of regenerative proteins
Programmed electrical signals intended to increase or decrease the body’s production or release of proteins involved in repair, inflammation and healthy aging, including Klotho, follistatin, BDNF and SIRT6.
Healthspan and organ function
Stimulation systems and treatment methods aimed at supporting muscle, brain, kidney, cardiovascular and other tissue functions.
Regenerative aesthetics
Technologies addressing skin repair, collagen-related signaling and tissue elasticity, with application-stage approaches for hair regeneration and repigmentation.
Regenerative cells and biologics
Klotho-producing stem cells and combinations of electrical stimulation with cells, peptides, exosomes and nutrient hydrogels.
Targeted delivery systems
Devices and proposed platforms designed to place, maintain, replenish or control regenerative materials near selected tissues or organs.
Cancer and biological electrical signals
Licensed technologies intended to record and modify cancer-cell electrical signals or promote cancer-cell death, alongside optioned systems for muscle control and responsive neurocode therapies.
Lionheart Health’s intellectual property portfolio supports its strategy of combining programmable bioelectric stimulation, controlled protein expression, regenerative biologics and targeted delivery for healthspan longevity, regenerative aesthetics and biological organ regeneration. Issued patents provide the foundation for protection, while pending applications and filings in development represent potential future coverage.